Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition.
Koch MS, Czemmel S, Lennartz F, Beyeler S, Rajaraman S, Przystal JM, Govindarajan P, Canjuga D, Neumann M, Rizzu P, Zwirner S, Hoetker MS, Zender L, Walter B, Tatagiba M, Raineteau O, Heutink P, Nahnsen S, Tabatabai G. Koch MS, et al. Neurooncol Adv. 2020 Sep 10;2(1):vdaa115. doi: 10.1093/noajnl/vdaa115. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33134924 Free PMC article.
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G. Skardelly M, et al. Among authors: koch m. Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30. Oncologist. 2017. PMID: 28360216 Free PMC article.
Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.
Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G. Rajaraman S, et al. Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29. Mol Ther Oncolytics. 2018. PMID: 30775418 Free PMC article.
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma.
Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G. Przystal JM, et al. Cancers (Basel). 2021 May 15;13(10):2400. doi: 10.3390/cancers13102400. Cancers (Basel). 2021. PMID: 34063518 Free PMC article.
Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.
Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar-Cordova E, Aguilar LK, Guzik BW, Barone F, Tak PP, Schregel K, Hoetker MS, Lederer JA, Chiocca EA, Tabatabai G, Lawler SE. Koch MS, et al. Mol Ther Oncolytics. 2022 Jul 31;26:275-288. doi: 10.1016/j.omto.2022.07.009. eCollection 2022 Sep 15. Mol Ther Oncolytics. 2022. PMID: 36032633 Free PMC article.
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.
Zdioruk M, Jimenez-Macias JL, Nowicki MO, Manz KE, Pennell KD, Koch MS, Finkelberg T, Wu B, Boucher P, Takeda Y, Li W, Piranlioglu R, Ling AL, Chiocca EA, Lawler SE. Zdioruk M, et al. Among authors: koch ms. Cell Rep Med. 2023 May 16;4(5):101019. doi: 10.1016/j.xcrm.2023.101019. Epub 2023 Apr 14. Cell Rep Med. 2023. PMID: 37060903 Free PMC article.
41 results